Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03268005 · ClinicalTrials.gov registry record · Phase 3
Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,264
- Enrollment target
NCT03268005: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT03268005 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 1,264 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (64% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03268005, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,264 participants
- Enrollment target
Study Summary
The study compares 2 medicines for type 2 diabetes: fast-acting insulin aspart (a new medicine) and NovoRapid®/NovoLog® (a medicine doctors can already prescribe). Fast-acting insulin aspart will be tested to see how well it works and if it is safe. Participants will get either fast-acting insulin aspart or NovoRapid®/ NovoLog® - which treatment you get is decided by chance. Both medicines will be taken together with insulin degludec. Participants will need to take 1 injection 4 times every day (all insulins will be provided in pens). The study will last for about 8 months (34 weeks).
Primary Outcome
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 16. The endpoint was evaluated based on data from the in-trial observation period. In-trial observation period was from date of randomisation and until last trial-related participant-site contact.
Interventions
- DRUG Metformin
- DRUG Insulin aspart
- DRUG Faster-acting insulin aspart
- DRUG Insulin degludec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,264 participants |
| Start Date | 2017-09-19 |
| Est. Completion | 2019-01-29 |
| Phase | Phase 3 |
What the finished NCT03268005 record still lists
NCT03268005 is an interventional study that assigns participants to a tested intervention. Its 1,264 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (64% higher).
The record links to 0 conditions, and to 4 interventions - of which Metformin is the first listed.
NCT03268005 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03268005 about?
NCT03268005 is a clinical study titled "Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes". The study compares 2 medicines for type 2 diabetes: fast-acting insulin aspart (a new medicine) and NovoRapid®/NovoLog® (a medicine doctors can already prescribe). Fast-acting insulin aspart will be tested to see how well it works and if it is safe. Participants will get either fast-acting insulin a...
What is the current status of trial NCT03268005?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,264 participants. The study started on 2017-09-19. Estimated completion is 2019-01-29.
What interventions are being tested in trial NCT03268005?
The interventions under investigation include: Metformin (DRUG), Insulin aspart (DRUG), Faster-acting insulin aspart (DRUG), Insulin degludec (DRUG).
Who is sponsoring clinical trial NCT03268005?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03268005's enrollment target sits among peer trials
1,264 203rd of 2000 higher than 1,797 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06119581 · 1,264 participants · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- NCT06712316 · 1,260 participants · Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- NCT06812273 · 1,260 participants · NA
Mediators and Moderators of Auditory Training
- NCT06931340 · 1,260 participants · Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI